Table 4.
Summary of bispecific T-cell antibody combinations for MM
| Name | Patient population | Trial phase | Combination drugs | Current status (ClinicalTrials.gov) |
|---|---|---|---|---|
| Elranatamab | RRMM | Phase 1b/2 | Arm 1: elranatamab + nirogacestat (GSI) | MagnetisMM-4 (recruiting) NCT05090566 |
| Arm 2: elranatamab + lenalidomide + dexamethasone | ||||
| Phase 3 | Arm 1: elranatamab | MagnetisMM-5 (recruiting) NCT05020236 | ||
| Arm 2: elranatamab + daratumumab | ||||
| Arm 3: earatumumab + pomalidomide + dexamethasone | ||||
| Teclistamab + talquetamab | RRMM | Phase 3 | Arm 1: teclistamab + daratumumab | MajestTEC-3 (recruiting) NCT05083169 |
| Arm 2: daratumumab + pomalidomide + dexamethasone | ||||
| Arm 3: daratumumab + bortezomib + dexamethasone | ||||
| Phase 1 | Arm 1: teclistamab + talquetamab | NCT04586426 (recruiting) | ||
| Arm 2: teclistamab + talquetamab + daratumumab | ||||
| Phase 1b | Arm 1: daratumumab + teclistamab | TRIMM-2 (recruiting) NCT04108195 | ||
| Arm 2: daratumumab + talquetamab | ||||
| Arm 3: daratumumab + talquetamab + pomalidomide | ||||
| Arm 4: daratumumab + teclistamab + pomalidomide | ||||
| Cevostamab | RRMM | Phase 1 | Arm 1: cevostamab | Recruiting NCT04910568 |
| Arm 2: cevostamab + pomalidomide + dexamethasone | ||||
| Arm 3: cevostamab + daratumumab + dexamethasone |
Note: This list is not exhaustive for all bispecific T-cell antibody combinations developed for MM.
GSI, gamma secretase inhibitor.